Monday, July 31, 2017

Nature Reviews Drug Discovery contents August 2017 Volume 16 Number 8 pp 513-586

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery

See Things Differently

Learn about Charles River's comprehensive imaging capabilities including PET, SPECT, MRI, MRS and autoradiography. Our PET services are supported by custom PET ligands available from a local cyclotron and novel methods like AIF.

MRI offerings include pharmacological MRI to map response to drugs and magnetic resonance spectroscopy to measure metabolite changes.
August 2017 Volume 16 Number 8Advertisement

Nature Reviews Drug Discovery cover
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38
In this issue
News and Analysis
Research Highlights

Also this month
 Featured article:
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis & Christian D. Klein


Genomics has met its match!


A powerful first-line phenotyping technology delivering a readout of the molecular phenotype and all its influences, both genetic and non-genetic. See how genomics and metabolomics are breaking through together.

Recommend to library
The National Institute on Drug Abuse is seeking a scientific executive with expertise in medications development, clinical trials, and the Food and Drug Administration's regulations to lead a preclinical and clinical research program focused on developing innovative treatment approaches for substance use disorders. For more information, please visit our website.

BioPharma DealmakersCompany Profiles and Partnering Opportunities

Technical Note: Simplify Production of Complex Proteins & Biologics

Producing high quality, functional proteins in a rapid and cost-effective manner can be challenging when dealing with complex or difficult-to-express proteins, particularly if cGMP-compliance is needed. Find out how implementing the right expression platform can transform your efforts. 

Download article now
Comment: Combination products: modernizing the regulatory paradigm
Nina L. Hunter & Rachel E. Sherman
p513 | doi:10.1038/nrd.2017.66
New opportunities to develop innovative — and often complex — products that combine drugs, devices and/or biological components are rapidly emerging, raising questions about how such products should be regulated. Here, we discuss the ongoing efforts of the FDA to develop a modern, transparent, flexible and consistent science-based regulatory approach for combination products.
Abstract | Full Text | PDF


Calls grow to tap the gold mine of human genetic knockouts
Asher Mullard
p515 | doi:10.1038/nrd.2017.139
A Human Knockout Project would systematically search for loss-of-function genetic mutations in humans to help uncover new drug targets.

FDA approvals for the first 6 months of 2017
Asher Mullard
p519 | doi:10.1038/nrd.2017.148

FDA approves first new sickle cell drug in 20 years
Asher Mullard
p519 | doi:10.1038/nrd.2017.149

New cancer vaccines show clinical promise
Asher Mullard
p519 | doi:10.1038/nrd.2017.150

Market watch: Strategies for biosimilars in emerging markets
Ajay Gautam
p520 | doi:10.1038/nrd.2017.113

Patent watch: Supreme Court decision favours biosimilars
Courtenay C. Brinckerhoff
p521 | doi:10.1038/nrd.2017.136

Joshua Gordon
p523 | doi:10.1038/nrd.2017.134
Joshua Gordon, Director of the National Institute of Mental Health, discusses the evolving RDoC framework for research into mental illnesses, and the appropriate balance between the funding of basic and clinical research.

Colorectal cancer drugs market
Sorcha Cassidy & Basharut A. Syed
p525 | doi:10.1038/nrd.2017.59
The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.



Infectious diseases: Decrypting Cryptosporidium
p527 | doi:10.1038/nrd.2017.147

Muscle disorders: FGF19 reduces muscle wasting
p528 | doi:10.1038/nrd.2017.132

Anticancer therapy: Neutrophils deliver the goods
p528 | doi:10.1038/nrd.2017.133

Cancer: RNA-based approaches target KRAS
p529 | doi:10.1038/nrd.2017.137

Infectious diseases: Soil-sifting snags new antibiotic
p530 | doi:10.1038/nrd.2017.141


Cardiovascular disease: CRHR2 blockade prevents heart failure | Type 2 diabetes: Broccoli extract lowers glucose levels | Neurodegenerative disorders: SRC-ABL inhibitors protect motor neurons | Cancer: mRNA-encoded bispecific antibodies eliminate tumours

Drug discovery
JOBS of the week
Drug discovery project leaders
PhD Student Positions and Postdoctoral Position on Antimicrobial Drug Discovery
Purdue University
Sr. investigator / Investigator III, Drug Discovery in Liver Diseas at China Novartis Institutes for Biomedical Research (CNIBR)
China Novartis Institutes for Biomedical Research (CNIBR)
Molecular Pathology Research Laboratory Head - Cancer Research / Biomarkers and Translational Research (M / F)
Boehringer Ingelheim
Postdoctoral Fellow - Parasitology - at the University of Sao Paulo
University of Sao Paulo, Brazil
More Science jobs from
Drug discovery
3rd world congress on pharmaceutics and drug discovery
Dubai, UAE
More science events from
Nature Milestones: Interactive antibody timeline 

Nature Milestones: Antibodies presents an interactive timeline on the history of antibodies covering everything from their initial description in antisera through to their application in immunotherapy. The timeline includes written content, video interviews and animations. 

Access the timeline free online


Opportunities and challenges in phenotypic drug discovery: an industry perspective
John G. Moffat, Fabien Vincent, Jonathan A. Lee, Jörg Eder & Marco Prunotto
p531 | doi:10.1038/nrd.2017.111
There has been a resurgence in interest in phenotypic drug discovery (PDD) approaches in recent years based on their potential to address the incompletely understood complexity of diseases and their promise of delivering first-in-class drugs. However, PDD approaches can also present considerable challenges, and this article focuses on the lessons learned by researchers engaged in PDD in the pharmaceutical industry, and discusses how PDD can best deliver value to drug discovery portfolios.
Abstract | Full Text | PDF

Focus on Disease models: reproducibility and translation 

Lab Animal, a Nature Research journal focusing on in vivo methods, research and technology with model organisms of human health & disease, presents a special Focus on reproducibility and translation of in vivo research with disease models. 

Access this Focus >

Produced with support from: 
Taconic Biosciences, Inc. 
Charles River


Breaking barriers to novel analgesic drug development
Ajay S. Yekkirala, David P. Roberson, Bruce P. Bean & Clifford J. Woolf
p545 | doi:10.1038/nrd.2017.87
Existing pain therapies are often inadequate or associated with side effects. Here, Woolf and colleagues discuss new and existing strategies for the development of improved pain therapeutics, highlighting key challenges and considerations in the clinical development of novel analgesics.
Abstract | Full Text | PDF

Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis & Christian D. Klein
p565 | doi:10.1038/nrd.2017.33
Flaviviruses, including dengue and Zika viruses, are of substantial public health concern. Klein and colleagues review the development of broad-spectrum antiviral agents that would target many of the known and potentially unknown flaviviruses. The benefits and caveats of molecules that target either viral proteins or host mechanisms exploited by these viruses are discussed.
Abstract | Full Text | PDF | Supplementary information

Corrigendum: Upcoming market catalysts in Q3 2017
Sonny Nghiem
p586 | doi:10.1038/nrd.2017.138
Full Text | PDF

Open for Submissions 

npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.

Explore the benefits of submitting your manuscript.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at:
(You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: